Recognizing Residual Inflammatory Risk and Preventing Recurrent Events in Patients With Atherosclerotic Cardiovascular Disease
True or False: In patients with residual inflammatory risk, lowering serum levels of C-reactive protein, without altering lipid levels, significantly decreases the incidence of recurrent cardiovascular events.
True. A landmark trial recently demonstrated proof-of-concept for the inflammatory hypothesis by demonstrating that achieving a targeted reduction in serum levels of C-reactive protein, without altering lipid levels, significantly decreases the incidence of recurrent cardiovascular events in patients with residual inflammatory risk.
Ridker PM, et al. N Engl J Med. 2017;377:1119-31.
Click the ‘Start’ button to learn more about applying this cutting-edge evidence to the care of patients with residual inflammatory disease risk.
Christie M. Ballantyne, MD
Vice Chair of Research, Department of Medicine
Chief, Cardiology and Cardiovascular Research
Professor of Medicine, Molecular and Human Genetics, and Molecular Physiology and Biophysics
Director, The Maria and Alando J. Ballantyne, M.D. Atherosclerosis Clinical Research Laboratory
Director, Center for Cardiometabolic Disease Prevention
Baylor College of Medicine
Paul M. Ridker, MD
Eugene Braunwald Professor of Medicine
Harvard Medical School
Director, Center for Cardiovascular Disease Prevention
Brigham and Women’s Hospital
Clinical Content Manager
Rebecca L. Julian, MS, ELS
Senior Manager, Editorial
Kathryn Schaefer, MSN, RN
Lead Nurse Planner
East Lansing, MI
Upon completion, participants should be able to:
- Describe the inflammatory processes involved in atheroma formation and the use of biomarkers in characterizing patients who have high residual inflammatory risk
- Integrate current clinical evidence regarding strategies for reducing residual inflammatory risk into clinical decision making for patients with chronic atherosclerotic CVD
This activity is intended for cardiologists, internists, and other clinicians who provide routine care for patients at risk of experiencing a recurrent cardiovascular event.
Series Overview/Statement of Need
Inflammation has long been recognized as a key component of the atherogenic cascade resulting in plaque formation, progression, and rupture in coronary artery disease. However, a deepening understanding of the distinctions between residual inflammatory risk and residual cholesterol risk among patients with chronic atherosclerotic cardiovascular disease (ASCVD) is laying the foundation for a paradigm shift in characterizing patients’ risk of recurrent events and tailoring treatment based on patient-specific factors. Several anti-inflammatory therapies are in late-stage clinical trials to investigate their effect on inflammatory biomarker levels and the rate of recurrent cardiovascular events. Furthermore, a landmark trial recently demonstrated proof-of-concept for the inflammatory hypothesis by finding that lowering serum levels of markers of inflammation, in the absence of altered lipid levels, significantly decreases the incidence of recurrent cardiovascular events. To facilitate the translation of cutting-edge evidence to the care of patients with residual inflammatory disease risk, cardiologists must have a sound understanding of how targeting inflammation may affect downstream events, as well as how emerging options may enhance the available treatment armamentarium for this high-risk patient population.
Provided by Med-IQ.
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medium/Method of Participation
This CME activity consists of a 0.75-credit publication. To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: February 14, 2018
Expiration Date: February 13, 2019
Estimated Time to Complete This Activity: 45 minutes
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Christie M. Ballantyne, MD
Consulting fees/advisory boards: Abbott Laboratories, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Esperion, F. Hoffman La-Roche Ltd., Ionis Pharmaceuticals, Inc., Matinas BioPharma Holdings, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc.
Paul M. Ridker, MD
Consulting fees/advisory boards: AstraZeneca, QuintilesIMS, Sanofi-aventis U.S. Inc., Teva Pharmaceuticals Industries Ltd.
Contracted research: Amgen, AstraZeneca, Kowa Pharmaceuticals America, Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Other: AstraZeneca, Siemens Corporation
The peer reviewers and activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
For questions or comments about this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or email firstname.lastname@example.org.
Microsoft Windows® 8, Windows 7
Mac OS 10.7 (Lion) or newer
Microsoft Internet Explorer 8.0 or later
Mozilla Firefox - latest version
Google Chrome - latest version
Apple Safari - latest version
Adobe Acrobat Reader® or Adobe Reader
Adobe Flash Player
Adobe Flash Player 9 or later
For technical support, go to http://www.med-iq.com/index.cfm?fuseaction=content.support.
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-statement/.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
© 2018 Med-IQ, Inc.
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.